Antibody anti il17

Abstract

The present invention relates to an in vitro method for evaluating the prognosis of an autoimmune or chronic inflammatory disease in an individual, comprising the following steps: a) determining (i) the level of an anti-IL-17 autoanitibody and/or (ii) the level of an [IL-17/anti-IL-17 autoantibody] complex in a biological sample of the individual, and b) comparing the level of autoantibody and/or of complex determined in step a) with a reference value, the comparison being indicative of the prognosis of an autoimmune or chronic inflammatory disease in said individual.

1 . An in vitro method for evaluating the prognosis of a chronic autoimmune or inflammatory disease in an individual, the chronic autoimmune or inflammatory disease being selected from: rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, Crohn's disease, vasculitis, an associated cardiovascular disease, myositis, hepatitis, inflammatory and autoimmune nephropathy, neutrophilic dermatosis, Verneuil's disease and uveitis; comprising the following steps:
 a) detecting (i) the level of an anti-IL-17A autoantibody and/or (ii) the level of an IL-17A/anti-IL-17A autoantibody complex in a biological sample from said individual, and   b) comparing the level of autoantibody and/or of IL-17A/anti-IL-17A autoantibody complex determined in step a) with a reference value, said comparison being indicative of the prognosis of the chronic autoimmune or inflammatory disease in said individual.   
     
     
         2 . The in vitro method as claimed in  claim 1 , wherein the method is for evaluating the prognosis of a chronic autoimmune or inflammatory disease in an individual for
 (i) determining the risk of bone destruction in said individual suffering from said chronic autoimmune or inflammatory disease; and/or   (ii) determining the chances of response, of said individual suffering from said chronic autoimmune or inflammatory disease, to a treatment comprising the administration of an IL-17A-inhibiting active ingredient; and/or   (iii) determining the efficacy of a treatment or of a prevention of bone destruction in said individual suffering from said chronic autoimmune or inflammatory disease, said treatment or said prevention consisting of the administration of an IL-17A-inhibiting active ingredient;   wherein the comparison in step b) is indicative of said risk of bone destruction (i), of said chances of response to said treatment (ii) and/or of the efficacy of said treatment or of said prevention of bone destruction (iii).   
     
     
         3 . The in vitro method as claimed in  claim 1 , wherein the biological sample is selected from: whole blood, plasma, serum, synovial fluid, cerebrospinal fluid, pleural fluid and peritoneal fluid. 
     
     
         4 . The in vitro method as claimed in  claim 1 , wherein step a) consists in detecting the level of an anti-IL-17A autoantibody in said biological sample. 
     
     
         5 . The in vitro method as claimed in  claim 1 , wherein step a) consists in detecting a level of an IL-17A/anti-IL-17A autoantibody complex in said biological sample. 
     
     
         6 . The in vitro method as claimed in  claim 1 , wherein step a) consists in isolating an anti-IL-17A autoantibody or a cell producing the autoantibody in said biological sample; and detecting (i) the level of the anti-IL-17A autoantibody and/or (ii) the level of an IL-17A/anti-IL-17A autoantibody complex. 
     
     
         7 . An in vitro method for isolating an anti-IL-17A autoantibody or a cell producing the autoantibody, comprising the following steps:
 a) selecting an individual with a chronic autoimmune or inflammatory disease selected from: rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, Crohn's disease, vasculitis, an associated cardiovascular disease, myositis, hepatitis, inflammatory and autoimmune nephropathy, neutrophilic dermatosis, Verneuil's disease and uveitis;   b) detecting an anti-IL-17A autoantibody and/or an IL-17A/anti-IL-17A autoantibody complex, or a cell producing the anti-IL-17A autoantibody in a biological sample from the individual; and   c) isolating the anti-IL-17A autoantibody or the cell producing the anti-IL-17A autoantibody from the biological sample of the individual.   
     
     
         8 . A method for treating or preventing a chronic autoimmune or inflammatory disease in an individual, the chronic autoimmune or inflammatory disease being selected from: rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, Crohn's disease, vasculitis, an associated cardiovascular disease, myositis, hepatitis, inflammatory and autoimmune nephropathy, neutrophilic dermatosis, Verneuil's disease and uveitis, comprising
 administering to the individual an IL-17A-inhibiting active ingredient. characterized in that the individual does not produce an anti-IL-17A autoantibody.   
     
     
         9 . The method as claimed in  claim 8 ; for treating or preventing (i) destructive rheumatoid arthritis or (ii) rheumatoid arthritis in an individual not producing anti-IL-17A autoantibody, or of bone destruction associated with either one of groups (i) and (ii), comprising
 administering to the individual an IL-17A-inhibiting active ingredient.   
     
     
         10 . The method as claimed in  claim 8 , wherein the IL-17-inhibiting active ingredient is an anti-IL-17A antibody. 
     
     
         11 . The method as claimed in  claim 9 , wherein the IL-17-inhibiting active ingredient is an anti-IL-17A antibody. 
     
     
         12 . The method as claimed in  claim 1 , wherein the chronic autoimmune or inflammatory disease is selected from: rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, Crohn's disease, vasculitis, myositis, hepatitis, inflammatory and autoimmune nephropathy, neutrophilic dermatosis, Verneuil's disease and uveitis. 
     
     
         13 . The method as claimed in  claim 7 , wherein the chronic autoimmune or inflammatory disease is selected from: rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, Crohn's disease, vasculitis, myositis, hepatitis, inflammatory and autoimmune nephropathy, neutrophilic dermatosis, Verneuil's disease and uveitis. 
     
     
         14 . The method as claimed in  claim 8 , wherein the chronic autoimmune or inflammatory disease is selected from: rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, Crohn's disease, vasculitis, myositis, hepatitis, inflammatory and autoimmune nephropathy, neutrophilic dermatosis, Verneuil's disease and uveitis.